Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Radiology and Oncology is Scopus-indexed (Q2, CiteScore 3.7), WoS SCIE, DOAJ. Published by Sciendo.
Checked against the index lists dated .
ISSN 1318-2099Verify ISSN ↗1581-3207Verify ISSN ↗
Publisher: Sciendo
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Radiology, Nuclear Medicine and Imaging | 145 / 361 | 59th | Q2 |
| Oncology | 231 / 428 | 46th | Q3 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1992–present, best quartile Q2, CiteScore 3.7.
Radiology and Oncology is Q2 in Radiology, Nuclear Medicine and Imaging (rank 145 of 361) and Q3 in Oncology (rank 231 of 428), by CiteScore 2025.
Radiology and Oncology is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.7, which places it in quartile Q2 at the 59th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.641, quartile Q2, with an H-index of 49.
The publisher lists an article processing charge of about US$970 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Radiology and Oncology is published by Sciendo. Its print ISSN is 1318-2099 and its online ISSN is 1581-3207.
Yes — indexed in the Science Citation Index Expanded.
Yes — it is an open-access journal, listed in DOAJ.
Radiology and Oncology has an h-index of 55 and a 2-year mean of 2.4 citations per paper (OpenAlex). Its Scopus CiteScore is 3.7, quartile Q2. On 2-year citations it ranks #84 of 346 Scopus journals in Radiology, Nuclear Medicine and Imaging.
Radiology and Oncology published 63 papers in 2025; its busiest recent year was 2020 with 73. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from Slovenia (53.2%), China (16.7%) and United States (4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. No retracted papers are recorded. The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.